Kiwi Biociences: Finalist in the Pharma Industry Awards featured in The Telegraph

Kiwi Biociences: Finalist in the Pharma Industry Awards featured in The Telegraph

Acknowledging a Significant Milestone

Kiwi Biosciences, a prominent Boston-based biotech startup, has achieved a remarkable feat by securing a finalist position in the Pharma Industry Awards UK 2023. This recognition underscores Kiwi Biosciences' unwavering dedication to excellence within the realm of biotechnology.


Achievements Featured in the Telegraph

Furthermore, Kiwi Biosciences earned the distinction of being mentioned in the renowned pages of the Telegraph. This acknowledgement is a testament to the pioneering work undertaken by Kiwi Biosciences, which has left an indelible mark on the field of digestive health.

David Hachuel, co-founder and COO at Kiwi, told the Telegraph:

“At Kiwi Biosciences, our mission has always been to make a meaningful difference in the lives of individuals with digestive disorders. We are honoured to be recognised by the Pharma Industry Awards, as it reaffirms our commitment to rigorous scientific research, the trust of our customers, and the potential for science to transform millions of lives. We are excited about the future and remain steadfast in our development of elegant solutions for extraordinary gut relief.”


At the core of Kiwi Biosciences' remarkable journey is their groundbreaking product, FODZYME. This revolutionary enzyme supplement stands as a testament to their dedication to transforming the lives of individuals grappling with digestive disorders.


Navigating the FODMAP Challenge

A considerable portion of the global population (up to 10%) wrestles with digestive discomfort arising from FODMAPs—short-chain carbohydrates encountered in various food items.

FODZYME, certified low-FODMAP by Monash University, represents a watershed moment in the realm of digestive health. It is meticulously engineered to break down prevalent FODMAP triggers found in foods such as garlic, onion, wheat, and others. The distinctive aspect of FODZYME lies in its innovative delivery mechanism — a versatile powder blend that effortlessly integrates with high-FODMAP meals.


The Triad of Enzymatic Expertise

FODZYME is fortified with three pivotal enzymes:

  1. Fructan Hydrolase: This enzyme takes on fructans, prevalent in wheat, onions, and garlic—an arduous FODMAP category.

  2. Alpha-Galactosidase: Targeting galacto-oligosaccharides (GOS) present in legumes and pulses, this enzyme offers relief.

  3. Lactase: For those grappling with lactose intolerance, this enzyme efficiently addresses lactose found in dairy products.


Meet the Visionaries Fueling FODZYME's Success

FODZYME is the brainchild of distinguished Harvard alumni, Anjie Liu and David Hachuel. Anjie, named in a Forbes 30 under 30 list in 2023, incorporates her personal journey with IBS into FODZYME's genesis. David's formidable background encompasses mathematics, machine learning, and epidemiology. Collaborating with world-class experts in enzymology, biotechnology, medicine, and nutrition, they meticulously honed FODZYME's formulation.


Ushering in a New Era of Digestive Health

Eminent physicians and gut health dietitians have widely endorsed FODZYME. It presents a powerful solution for reintroducing a broad spectrum of foods into the diets of individuals who have long grappled with dietary restrictions.

Amidst a landscape where dietary limitations have been the norm for countless individuals, FODZYME by Kiwi Biosciences emerges as a harbinger of hope. Kiwi Biosciences' elevation as a finalist in the Pharma Industry Awards UK 2023, coupled with their mention in the Telegraph, fortify their commitment to pioneering scientific advancement and catalyzing transformative change in the domain of digestive health.

Anticipate forthcoming developments from Kiwi Biosciences as they remain steadfast in their mission to offer elegant solutions for extraordinary gut relief.

Related Posts